Clinical Trends for December 2017

Ryan Syrek, MA


December 22, 2017

Clinical Trend of the Week (December 9-15): Lymphoma Cancer

Approval of a new drug for cancer patients who have already undergone therapy resulted in this week’s top search term. Brentuximab vedotin (Adcetris®) has been approved by the US Food and Drug Administration (FDA) for use in patients with cutaneous T-cell lymphoma (CTCL) who previously underwent systemic therapy. Specifically, the drug was approved for the most common subtypes of CTCL, which are primary cutaneous anaplastic large-cell lymphoma and CD30-expressing mycosis fungoides.

CTCL has no definitive cure and is a disfiguring blood cancer of the skin, making new treatment options particularly encouraging to patients and healthcare providers confronting the condition. Brentuximab vedotin targets CD30 and was previously approved for use in certain patients with classic Hodgkin lymphoma; it also has an accelerated approval for use in some patients with systemic anaplastic large-cell lymphoma. Given the severity of CTCL and relatively few treatment options, the latest approval for this drug is welcome news to many.

For more information on cutaneous T-cell lymphoma, read here


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.